BioPorto A/S · OMXCOP:BIOPOR

BioPorto A/S — Q3 2026 Earnings Presentation

13 slides from BioPorto A/S's earnings presentation, Nov 19, 2026

  1. Slide 1: BioPorto Business Update Q3 2026

    BioPorto Business Update Q3 2026 November 19, 2026 Carsten Buhl, CEO, & Klaus Juhl Wulff, CFO 1

  2. Slide 2: Forward-looking Statements

    Forward-looking Statements References herein to this presentation shall mean and include this forward-looking statements to reflect subsequent events or document, any oral presentation accompanying this document provided circumstances after the date of this presentation. by BioPorto A/S (the “Compan

  3. Slide 3: Who is BioPorto

    Who is BioPorto A Danish in vitro diagnostics company making kidney injury actionable The Kidney In vitro diagnostics improve kidney health and quality of lives through actionable Biomarkers enabling clinicians to know earlier, manage better with confidence and thereby transform globally kidney care

  4. Slide 4: Q3-26 confirms progress from focused execution

    Q3-26 confirms progress from focused execution Solid quarter → market relevance strengthening → strategy advancing 73% 5 Adult Q3 US growth New hospitals Market validation initiated Strong quarter driven by NGAL adoption Adoption expanding in key accounts Next step beyond pediatric use Kidney Forwar

  5. Slide 5: The "Forward" Strategic Plan

    The ”Forward” Strategic Plan Focus on execution of Market Access & Commercialization to transform kidney care ASPIRATIONS + 60 U.S. Hospitals 2H 2028 Cash 1 Adoption + Validation Study 2026 Flow Positive + 100 Global Hospitals FY 2028 Revenue 2 High Growth + Adult Indication 2027 135-185m DKK + 170

  6. Slide 6: Growth & Adoption; Commercialization

    Growth & Adoption; Commercialization Solid growth from markets in focus and adoption progresses as planned Quarterly sales growth in focused markets Development of # of US Hospitals from 2024-2026 On track to reach annual target at 60+ 59 73% 48 54 US Q326 growth vs. Q3-25 43 44 37 37 36 2024 Q125 Q

  7. Slide 7: Adult Validation Study; Market Access

    Adult Validation Study; Market Access Progressing as planned; and focuses on the $700M market at ICU Market access rests on three dimensions Adult Validation Study – progress From now to FDA adult clearance Indications ✓ Now 1 Today: pediatric ICU AKI risk stratification – Validation Study initiatin

  8. Slide 8: Growing focus on kidney injury & earlier detection

    Growing focus on kidney injury & earlier detection A global shift from late-stage treatment to earlier intervention to address the cost burden Kidney health: a space gaining global attention BioPorto’s journey: actionable kidney biomarkers 674 Millions live with kidney disease WHO, May 2025 1:5 Hosp

  9. Slide 9: NGAL Sales US continuing strong growth

    NGAL Sales US continuing strong growth US NGAL RUO sales (accumulated 12 months rolling at constant exchange rates) DKKm 30 26,3 +63% 25 Q3 2025 → Q3 2026 22,8 19,3 20 17,8 16,1 15,1 15 13,7 14,2 13,0 11,8 12,3 10,1 10,2 10 8,7 DKK 26.3M 12-month rolling US 5 NGAL RUO sales Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q

  10. Slide 10: Q3 revenue up 28% and US NGAL up 73%

    Q3 revenue up 28% and US NGAL up 73% US RUO NGAL revenue up 73%, total NGAL revenue of DKK 8.8M up 23% vs. Q3 2025 (constant currency) Total revenue of DKK 9.7 million, up 28%* like-for-like vs. Q3 2025 (currency neutral) Adjusted EBITDA loss of DKK 16.8M, flat vs. Q3 2025 (improved excl. divested A

  11. Slide 11: 2026 Financial Guidance

    2026 Financial Guidance Unchanged following the AntiBody divestment in April Total revenue Total NGAL revenue Adjusted EBITDA loss 38-48 33-42 58-68 DKK million DKK million DKK million Original guidance: 48-58* Original guidance: 33-42* Original guidance: 50-60* Expected NGAL revenue growth of 20-50

  12. Slide 12: Why BioPorto as the investment

    Why BioPorto as the investment An opportunity at the changing intersection of diagnostics & kidney care Large Unmet Need Proven Technology Regulatory & KOL Foundation $700m $3bn- Competitive Position Market Opportunity Scalable Growth 12 © Copyright BioPorto |

  13. Slide 13: Questions & Answers

    Questions & Answers IR Contact Klaus Juhl Wulff, CFO – kjw@bioporto.com +45 2563 3990 | bioporto.com © Copyright BioPorto |

BioPorto — Q3 2026 Earnings Presentation on 6ix